Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00243503. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of tumor control and survival; assess patient reported outcomes; assess PK in combination with trastuzumab and compare efficacy and safety.
Study identification
- NCT ID
- NCT00243503
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 60 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2006 (Type not available)
- Primary completion
- Apr 2009 (Actual)
- Completion
- Jul 2010 (Actual)
- Last update posted
- Jul 22, 2011
2006 – 2010
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Montgomery | Alabama | 36106 | — |
| Pfizer Investigational Site | Newark | Delaware | 19713 | — |
| Pfizer Investigational Site | Newark | Delaware | 19718-6001 | — |
| Pfizer Investigational Site | Wilmington | Delaware | 19899 | — |
| Pfizer Investigational Site | Fort Lauderdale | Florida | 33308 | — |
| Pfizer Investigational Site | Harvey | Illinois | 60426 | — |
| Pfizer Investigational Site | Tinley Park | Illinois | 60477 | — |
| Pfizer Investigational Site | Munster | Indiana | 46321 | — |
| Pfizer Investigational Site | Lafayette | Louisiana | 70503 | — |
| Pfizer Investigational Site | New Iberia | Louisiana | 70563 | — |
| Pfizer Investigational Site | Corinth | Mississippi | 38834 | — |
| Pfizer Investigational Site | Southaven | Mississippi | 38671 | — |
| Pfizer Investigational Site | Las Vegas | Nevada | 89135 | — |
| Pfizer Investigational Site | New York | New York | 10021 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38104 | — |
| Pfizer Investigational Site | Memphis | Tennessee | 38120 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00243503, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 22, 2011 · Synced Nov 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.